Verona Pharma 宣布IPO发行价为每股13.50美元
2017年4月6日 来源Renaissance Capital
摘要：专注于呼吸系统疾病治疗的Verona Pharma公司今日发行580万股普通股，筹集资金7800万美元， 其IPO发行价为每股13.50美元，符合每股13.49 美元的预期售价，公司计划在纳斯达克上市，股票代码为VRNA。Jefferies 和 Stifel 为此笔交易的负责人。
Verona Pharma, which is developing inhaled treatments for respiratory diseases, raised $78 million by offering 5.8 million shares at $13.50, in line with the expected price of $13.49. Verona Pharma plans to list on the Nasdaq under the symbol VRNA. Jefferies and Stifel acted as lead managers on the deal.
The article Verona Pharma prices IPO at $13.50 originally appeared on IPO investment manager Renaissance Capital’s web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital’s research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.